<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308581</url>
  </required_header>
  <id_info>
    <org_study_id>C87042</org_study_id>
    <secondary_id>Eudract number: 2005-004104-37</secondary_id>
    <nct_id>NCT00308581</nct_id>
  </id_info>
  <brief_title>Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab</brief_title>
  <official_title>Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over
      26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with
      infliximab
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Response is defined as at least 100 point decrease in CDAI score from baseline. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase</measure>
    <time_frame>Week 6</time_frame>
    <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 26</time_frame>
    <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 2 of the Induction Phase</measure>
    <time_frame>Week 2</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 4 of the Induction Phase</measure>
    <time_frame>Week 4</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 6 of the Induction Phase</measure>
    <time_frame>Week 6</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 8 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 8</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 10 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 10</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 12 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 12</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 14 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 14</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 16 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 16</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 18 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 18</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 20 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 20</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 22 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 22</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 24 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 24</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI Score at Week 26 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 26</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 2 of the Induction Phase</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 4 of the Induction Phase</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 6 of the Induction Phase</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 10</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 14</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 22</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 10</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 12</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 14</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 16</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 18</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 20</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 22</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 24</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 26</time_frame>
    <description>Remission is defined as CDAI score ≤ 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 10</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 12</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 14</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 16</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 18</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 20</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 22</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 24</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</measure>
    <time_frame>Week 26</time_frame>
    <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase</measure>
    <time_frame>Week 0</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 2 of the Induction Phase</measure>
    <time_frame>Week 2</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 4 of the Induction Phase</measure>
    <time_frame>Week 4</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 6 of the Induction Phase</measure>
    <time_frame>Week 6</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 8 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 8</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 10 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 10 (optional measurement)</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 12 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 12</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 14 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 14 (optional measurement)</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 16 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 16</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 18 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 18 (optional measurement)</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 20 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 20</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 22 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 22 (optional measurement)</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 24 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 24</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Week 26 in the Randomized Maintenance Phase</measure>
    <time_frame>Week 26</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase</measure>
    <time_frame>Last visit on or before Week 26</time_frame>
    <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L. Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Active 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Q4W regimen
- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Q2W regimen
- every 2 weeks: 400 mg Certolizumab Pegol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>400mg Certolizumab Pegol, Q4W, administered 4-weekly</description>
    <arm_group_label>Active 1</arm_group_label>
    <other_name>CDP870</other_name>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>400mg Certolizumab Pegol, Q2W, administered 2-weekly</description>
    <arm_group_label>Active 2</arm_group_label>
    <other_name>CDP870</other_name>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo administered 4-weekly in Active 1</description>
    <arm_group_label>Active 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Crohn's Disease

          -  Previous treatment failure to Infliximab (intolerance and/or no response)

        Exclusion Criteria:

          -  Obstructive intestinal strictures

          -  Recent bowel resection

          -  Proctocolectomy or total colectomy

          -  Current total parenteral nutrition

          -  Short bowel syndrome

          -  All concomitant diseases or pathological conditions that could interfere with Crohn's
             disease assessment or to be harmful for the well being of the patient

          -  Previous clinical trials and previous biological therapy that could interfere with the
             results in the present clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberpullendorf</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble, Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier, Cédex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>Cedex 3</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse, Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terneuven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromso</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.cimzia.com/pdf/Prescribing_Information.pdf</url>
    <description>Product Information</description>
  </link>
  <reference>
    <citation>Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug;38(4):1213-24.</citation>
    <PMID>20925993</PMID>
  </reference>
  <results_reference>
    <citation>Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6.</citation>
    <PMID>20451663</PMID>
  </results_reference>
  <results_reference>
    <citation>Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.</citation>
    <PMID>21223344</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2006</study_first_submitted>
  <study_first_submitted_qc>March 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <results_first_submitted>July 7, 2009</results_first_submitted>
  <results_first_submitted_qc>October 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2009</results_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Certolizumab pegol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 539 subjects that have been enrolled in the induction phase, 373 have been included in the randomized maintenance phase. The Baseline Characteristics module only includes the Intent-to-treat (ITTI) population of the induction phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Q4W Regimen</title>
          <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
        </group>
        <group group_id="P2">
          <title>Q2W Regimen</title>
          <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
        </group>
        <group group_id="P3">
          <title>Overall</title>
          <description>Overall Induction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Not applicable in this period</participants>
                <participants group_id="P2" count="0">Not applicable in this period</participants>
                <participants group_id="P3" count="539"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Not applicable in this period</participants>
                <participants group_id="P2" count="0">Not applicable in this period</participants>
                <participants group_id="P3" count="373"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="166"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to Q2W open-label treatment</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Overall Induction</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="539"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.67" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Intent-to-treat Induction Phase (ITTI) population: subjects who received at least one dose of study drug in the induction phase</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>Intent-to-treat Induction Phase (ITTI) population: subjects who received at least one dose of study drug in the induction phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase</title>
        <description>Response is defined as at least 100 point decrease in CDAI score from baseline. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Intent-to-treat Randomized Maintenance Phase (ITTR) population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase</title>
          <description>Response is defined as at least 100 point decrease in CDAI score from baseline. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>Intent-to-treat Randomized Maintenance Phase (ITTR) population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With a sample size of 165 patients per treatment arm, assuming a percentage of responders of 45% with the Q4W regimen, the study had 80% power to show a statistically significant difference in percentage of responders at Week 26 between the two treatment groups, when there is a true difference of 16% in percentage of responders in favor of the Q2W regimen, and using a 2-sided chi-square at the 5% significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.696</p_value>
            <p_value_desc>Logistic regression model including terms for treatment arm and geographical region (North America versus Europe).</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Direction of comparison is Q4W regimen (active 1) versus Q2W regimen (active 2).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase</title>
        <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase</title>
          <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase</title>
        <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase</title>
          <description>Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase</title>
        <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 6</time_frame>
        <population>ITTI population: subjects who received at least one dose of study drug in the induction phase</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase</title>
          <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: subjects who received at least one dose of study drug in the induction phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase</title>
        <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase</title>
          <description>Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 2 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 2</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 2 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.53" spread="97.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 4 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 4</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 4 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.87" spread="101.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 6 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 6</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 6 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.81" spread="103.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 8 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 8</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 8 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.62" spread="94.08"/>
                    <measurement group_id="O2" value="169.18" spread="86.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 10 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 10</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 10 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.65" spread="98.16"/>
                    <measurement group_id="O2" value="162.86" spread="88.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 12 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 12 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.83" spread="103.89"/>
                    <measurement group_id="O2" value="163.78" spread="96.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 14 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 14</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 14 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.34" spread="99.74"/>
                    <measurement group_id="O2" value="158.68" spread="90.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 16 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 16</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 16 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.73" spread="103.65"/>
                    <measurement group_id="O2" value="156.05" spread="90.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 18 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 18</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 18 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.38" spread="95.65"/>
                    <measurement group_id="O2" value="156.64" spread="90.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 20 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 20</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 20 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.79" spread="112.53"/>
                    <measurement group_id="O2" value="138.60" spread="80.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 22 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 22</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 22 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.13" spread="85.34"/>
                    <measurement group_id="O2" value="141.89" spread="90.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 24 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 24</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 24 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.49" spread="99.92"/>
                    <measurement group_id="O2" value="139.50" spread="75.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDAI Score at Week 26 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CDAI Score at Week 26 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.37" spread="87.49"/>
                    <measurement group_id="O2" value="131.41" spread="79.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 2 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 2 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.57" spread="85.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 4 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 4 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.63" spread="93.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 6 of the Induction Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 6 of the Induction Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-120.33" spread="90.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-133.35" spread="85.90"/>
                    <measurement group_id="O2" value="-137.70" spread="75.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 10</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-145.16" spread="90.76"/>
                    <measurement group_id="O2" value="-145.26" spread="76.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-134.51" spread="91.52"/>
                    <measurement group_id="O2" value="-145.17" spread="78.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 14</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-145.54" spread="86.85"/>
                    <measurement group_id="O2" value="-144.08" spread="86.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141.90" spread="98.56"/>
                    <measurement group_id="O2" value="-144.89" spread="83.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 18</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-150.38" spread="88.68"/>
                    <measurement group_id="O2" value="-144.66" spread="85.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-139.98" spread="104.52"/>
                    <measurement group_id="O2" value="-162.85" spread="80.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 22</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-171.52" spread="82.56"/>
                    <measurement group_id="O2" value="-159.13" spread="88.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-165.06" spread="90.54"/>
                    <measurement group_id="O2" value="-160.44" spread="76.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase</title>
        <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase</title>
          <description>The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-176.85" spread="80.44"/>
                    <measurement group_id="O2" value="-168.59" spread="77.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Loss of Response (CDAI Score &gt; 150 and Minimum Increase in CDAI of 70) After Week 6</title>
        <description>Median time to loss of response in the maintenance period (from Kaplan-Meier analysis); range is time of first event to time of last event. Loss of response is defined as both a CDAI score &gt; 150 points and a minimum increase in CDAI of 70 points versus Week 6 at two consecutive visits.</description>
        <time_frame>Week 6 to Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Loss of Response (CDAI Score &gt; 150 and Minimum Increase in CDAI of 70) After Week 6</title>
          <description>Median time to loss of response in the maintenance period (from Kaplan-Meier analysis); range is time of first event to time of last event. Loss of response is defined as both a CDAI score &gt; 150 points and a minimum increase in CDAI of 70 points versus Week 6 at two consecutive visits.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="10" upper_limit="133"/>
                    <measurement group_id="O2" value="125" lower_limit="14" upper_limit="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 10</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 12</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 14</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 16</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 18</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 20</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 22</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 24</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Remission is defined as CDAI score ≤ 150.</description>
        <time_frame>Week 26</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Remission is defined as CDAI score ≤ 150.</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 10</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 12</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 14</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 16</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 18</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 20</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 22</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 24</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
        <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
        <time_frame>Week 26</time_frame>
        <population>ITTR population taking steroids at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.</title>
          <description>Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).</description>
          <population>ITTR population taking steroids at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 0</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="2.5" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 2 of the Induction Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 2</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 2 of the Induction Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.3" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 4 of the Induction Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 4</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 4 of the Induction Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.2" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 6 of the Induction Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 6</time_frame>
        <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Overall Induction</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 6 of the Induction Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTI population: all subjects who received at least one dose of study drug in the induction phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.4" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 8 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 8</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 8 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.4" upper_limit="20.4"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1.2" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 10 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 10 (optional measurement)</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 10 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.3" lower_limit="4.3" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 12 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 12</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 12 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.8" upper_limit="18.9"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.3" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 14 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 14 (optional measurement)</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 14 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.6" upper_limit="0.6"/>
                    <measurement group_id="O2" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 16 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 16</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 16 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="1.8" upper_limit="19.4"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.3" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 18 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 18 (optional measurement)</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 18 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="3.4" upper_limit="110.2"/>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 20 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 20</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 20 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="1.9" upper_limit="26.0"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.6" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 22 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 22 (optional measurement)</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 22 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements, measurements are optional)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13.0" lower_limit="1.6" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 24 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 24</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 24 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.6" upper_limit="24.4"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1.7" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Week 26 in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
        <time_frame>Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Week 26 in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.6" upper_limit="17.0"/>
                    <measurement group_id="O2" value="5.1" lower_limit="1.5" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase</title>
        <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L. Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.</description>
        <time_frame>Last visit on or before Week 26</time_frame>
        <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
        <group_list>
          <group group_id="O1">
            <title>Q4W Regimen</title>
            <description>every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol</description>
          </group>
          <group group_id="O2">
            <title>Q2W Regimen</title>
            <description>every 2 weeks: 400 mg Certolizumab Pegol</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase</title>
          <description>High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L. Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.</description>
          <population>ITTR population: subjects who were randomized and received at least one dose of study drug in the randomized maintenance phase (available measurements)</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="1.9" upper_limit="22.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.5" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported here for the induction phase + safety follow-up period following induction, and for the randomized maintenance phase + safety follow-up period following maintenance.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Q4W Regimen</title>
          <description>Subjects who were randomized to and received Q4W regimen (every 2 weeks: alternatively placebo and 400 mg Certolizumab Pegol); randomized maintenance phase + safety follow-up period following randomized maintenance phase.</description>
        </group>
        <group group_id="E2">
          <title>Q2W Regimen</title>
          <description>Subjects who were randomized to and received Q2W regimen (every 2 weeks: 400 mg Certolizumab Pegol); randomized maintenance phase + safety follow-up period following randomized maintenance phase.</description>
        </group>
        <group group_id="E3">
          <title>Induction Phase</title>
          <description>Overall population in the Induction phase + safety follow-up period following induction phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Douglas' abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Hyperhomocysteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="277" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E3" events="42" subjects_affected="40" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E3" events="65" subjects_affected="58" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="187"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E3" events="48" subjects_affected="44" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Pyrexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="187"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E3" events="53" subjects_affected="46" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 9.0">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="187"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="186"/>
                <counts group_id="E3" events="43" subjects_affected="41" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Arthralgia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E3" events="62" subjects_affected="51" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.0">Headache</sub_title>
                <counts group_id="E1" events="53" subjects_affected="31" subjects_at_risk="187"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E3" events="95" subjects_affected="86" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB Pharma</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

